Form 8-K
8-K — AIxCrypto Holdings, Inc.
Accession: 0001493152-26-023124
Filed: 2026-05-14
Period: 2026-05-12
CIK: 0001460702
SIC: 6199 (FINANCE SERVICES)
Item: Entry into a Material Definitive Agreement
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-10.1 (ex10-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001460702
0001460702
2026-05-12
2026-05-12
0001460702
dei:FormerAddressMember
2026-05-12
2026-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 12, 2026
AIxCrypto
Holdings, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
001-37428
26-3474527
(State
or Other Jurisdiction
(Commission
(I.R.S.
Employer
of
Incorporation)
File
Number)
Identification
No.)
1990
E. Grand Ave.
El
Segundo, California
90245
(Address
of Principal Executive Offices)
(Zip
Code)
Registrant’s
Telephone Number, Including Area Code: (760) 452-8111
5857
Owens Avenue, Suite 300
Carlsbad,
California 92008
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $0.001
AIXC
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
May 12, 2026, the AIxCrypto Holdings, Inc., a Delaware corporation (the “Company”), entered into a note purchase agreement
(the “Note Purchase Agreement”) with CABG ACQUISITION CORP. (“Buyer”), pursuant to which the Company agreed to
sell, assign, and transfer to the Buyer, all of the Company’s right, title, and interest in the Note Package (as such term is defined
in the Note Purchase Agreement), which includes (a) that certain Amended and Restated Secured Demand Promissory Note dated August 21,
2025, as amended by Amendment No. 1 dated September 15, 2025 and Amendment No. 2 dated October 2, 2025 (collectively, the “Note”),
made by Marizyme, Inc., a Nevada corporation (“Marizyme”), in favor of the Company, in the outstanding principal amount of
approximately $4,771,142, together with accrued and unpaid interest thereon at the rate of eighteen percent (18%) per annum (the Note,
together with all accrued and unpaid interest and all other amounts due thereunder, the “Note Obligations”); (b) that certain
Co-Development Note dated April 11, 2024, by and between Marizyme and the Company (as successor to Qualigen Therapeutics, Inc.), as amended
by Amendment No. 1 to Co-Development Note dated August 6, 2024, providing for a funding amount of $1,750,000 and an Investment Return
payable to the Company based on the commercial success of the DuraGraft product, together with all rights of Company thereunder (the
“Co-Development Note”); (c) that certain Security Agreement dated August 20, 2025, by and between Marizyme, as debtor, and
the Company, as secured party (the “Security Agreement”), granting the Company a security interest in substantially all assets
of Marizyme (the “Collateral”); (d) all UCC financing statements filed in connection with the Security Agreement; (e) any
and all rights of the Company as a secured creditor of Marizyme with respect to the Collateral; and (f) all rights to collect, enforce,
or receive payment of the Note Obligations and any amounts due under the Co-Development Note.
The
total consideration for the sale of the Note Package under the Note Purchase Agreement includes, amongst others, a cash consideration
of $100,000 pursuant to Article 3.1 of the Note Purchase Agreement, royalty payments equal to ten percent (10%) of Net Revenue (as such
term is defined in the Note Purchase Agreement) on all cumulative Net Revenue exceeding $20,000,000 pursuant to Article 3.2 of the Note
Purchase Agreement, and a commitment by Buyer to acquire and commercialize, or cause another entity organized by Buyer to acquire and
commercialize, the assets of Marizyme, and to issue to the Company a membership interest equal to 4.99% of the outstanding membership
interests in the Buyer. Additionally, the Company will have a customary preemptive right, in the event the Buyer proposes to issue any
new membership interests other equity securities, and the Company will also have customary registration rights with respect to the membership
interest of the Buyer acquired by the Company, in the event that the Buyer or any successor entity converts to a corporation or otherwise
becomes subject to the Securities Act of 1933, as amended, in connection with a public offering or otherwise.
The
closing of the transactions contemplated under the Note Purchase Agreement shall occur on such date as the parties may mutually agree
in writing (the “Closing Date”), and shall be effective as of the Closing Date. If the closing has not occurred on or before
90 days from execution, either party may terminate the Note Purchase Agreement upon written notice to the other without further liability,
provided the terminating party is not then in material breach of its obligations.
The
foregoing descriptions of the Note Purchase Agreement do not purport to be complete and are qualified in its entirety by reference to
the full text of the Note Purchase Agreement, which is filed as Exhibit 10.1 to this Form 8-K and incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
10.1
NOTE PURCHASE AGREEMENT, dated May 12, 2026, by and between AIxCRYPTO HOLDINGS, INC. and CABG ACQUISITION CORP.
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
AIxCrypto
Holdings, Inc.
Date:
May 14, 2026
By:
/s/
Koti Meka
Name:
Koti
Meka
Title:
Chief
Financial Officer
EX-10.1
EX-10.1
Filename: ex10-1.htm · Sequence: 2
Exhibit 10.1
NOTE
PURCHASE AGREEMENT
by
and between
AIxCRYPTO HOLDINGS, INC.
formerly
known as Qualigen Therapeutics, Inc.
as
Seller,
and
CABG
ACQUISITION CORP.,
as
Buyer
Dated
as of May 12, 2026
This
NOTE PURCHASE AGREEMENT (this “Agreement”) is entered into as of May 12, 2026 (the “Effective Date”), by and
between AIxCrypto Holdings, Inc. (formerly known as Qualigen Therapeutics, Inc.), a Delaware corporation (“Seller”), and
CABG Acquisition Corp., a New York limited liability company (“Buyer”). Seller and Buyer are each referred to herein individually
as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS,
AIxCrypto Holdings, Inc. (formerly known as Qualigen Therapeutics, Inc.) is the holder of that certain Amended and Restated Secured
Demand Promissory Note dated August 21, 2025, as amended by Amendment No. 1 dated September 15, 2025 and Amendment No. 2 dated
October 2, 2025 (collectively, the “Note”), made by Marizyme, Inc., a Nevada corporation (“Marizyme”), in
favor of Seller, in the outstanding principal amount of approximately $4,771,142, together with accrued and unpaid interest
thereon at the rate of eighteen percent (18%) per annum (the Note, together with all accrued and unpaid interest and all other
amounts due thereunder, the “Note Obligations”);
WHEREAS,
the Note is secured by that certain Security Agreement dated August 20, 2025, by and between Marizyme, as debtor, and Seller, as secured
party (the “Security Agreement”), granting Seller a security interest in substantially all assets of Marizyme (the “Collateral”);
WHEREAS,
Seller’s name was changed from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. effective November 14, 2025, pursuant to
a Certificate of Amendment to the Certificate of Incorporation filed with the Delaware Secretary of State, a copy of which is attached
hereto as Exhibit C;
WHEREAS,
Buyer is a newly formed New York limited liability company organized for the purpose of acquiring the assets of Marizyme;
WHEREAS,
Seller desires to sell, assign, and transfer to Buyer, and Buyer desires to purchase and accept from Seller, all of Seller’s right,
title, and interest in and to the Note, the Security Agreement, and all related creditor rights, on the terms and conditions set forth
herein;
1
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
ARTICLE
1
DEFINITIONS
1.1 “Note
Package” means, collectively: (a) the Note; (b) the Co-Development Note (as defined in Section 1.5); (c) the Security Agreement;
(d) all UCC financing statements filed in connection with the Security Agreement; (e) any and all rights of Seller as a secured creditor
of Marizyme with respect to the Collateral; and (f) all rights to collect, enforce, or receive payment of the Note Obligations and any
amounts due under the Co-Development Note.
1.2 “Net
Revenue” means, with respect to any product or technology commercialized by CABG SPV (as defined in Section 3.3) utilizing
the assets of Marizyme, gross revenue actually received by CABG SPV from third parties in arm’s-length transactions, less only
the royalties owed by CABG SPV to the original owner of DuraGraft pursuant to any pre-existing license or royalty agreement to which
CABG SPV is bound. For the avoidance of doubt, no other deductions, offsets, returns, chargebacks, taxes, or expenses shall reduce Net
Revenue unless expressly agreed in writing by Seller.
1.3 “Royalty
Cap” means Five Million Six Hundred Seventy-One Thousand One Hundred Forty-Two Dollars ($5,671,142), representing the approximate
present value of the Note Obligations as of the date of this Agreement. For the avoidance of doubt, the Royalty Cap applies solely to
royalty payments on Net Revenue under Section 3.2 and does not limit or cap any Investment Return or other amounts payable to Seller
under the Co-Development Note.
1.4 “Co-Development
Note” means that certain Co-Development Note dated April 11, 2024, by and between Marizyme and Seller (as successor to Qualigen
Therapeutics, Inc.), as amended by Amendment No. 1 to Co-Development Note dated August 6, 2024, providing for a funding amount of $1,750,000
and an Investment Return payable to Seller based on the commercial success of the DuraGraft product, together with all rights of Seller
thereunder.
1.5 “Closing”
means the consummation of the transactions contemplated by this Agreement in accordance with Article 5.
ARTICLE
2
PURCHASE
AND SALE; ASSIGNMENT
2.1 Purchase
and Sale. Subject to the terms and conditions of this Agreement, at the Closing, Seller hereby sells, assigns, transfers, and conveys
to Buyer, and Buyer hereby purchases and accepts from Seller, all of Seller’s right, title, and interest in and to the Note Package,
free and clear of any liens, claims, or encumbrances created by Seller or, to Seller’s actual knowledge, consented to by Seller
(other than those existing under the Note Package itself).
2.2
Quitclaim Basis. THE ASSIGNMENT OF THE NOTE PACKAGE IS MADE ON A QUITCLAIM BASIS EXCEPT AS EXPRESSLY SET FORTH IN ARTICLE 4A HEREOF.
SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO: (a) THE COLLECTABILITY OR ENFORCEABILITY OF THE NOTE OR ANY NOTE
OBLIGATION; (b) THE PERFECTION, PRIORITY, OR SUFFICIENCY OF ANY SECURITY INTEREST GRANTED UNDER THE SECURITY AGREEMENT OR ANY FINANCING
STATEMENT FILED IN CONNECTION THEREWITH; (c) THE FINANCIAL CONDITION OR SOLVENCY OF MARIZYME; OR (d) THE VALUE OF ANY COLLATERAL. SUBJECT
TO ARTICLE 4A HEREOF, BUYER ACCEPTS THE NOTE PACKAGE IN ITS “AS-IS, WHERE-IS” CONDITION AND ASSUMES ALL RISKS ASSOCIATED
THEREWITH.
2
2.3 Assumption.
Buyer hereby assumes all obligations of Seller as holder of the Note Package arising after the Closing Date, including any obligations
of a secured creditor under applicable law with respect to the Collateral. Seller retains no liability with respect to the Note Package
arising after the Closing Date.
2.4 Notification
to Marizyme. Promptly following the Closing, Buyer shall provide written notice to Marizyme of the assignment of the Note and the
Security Agreement, in form and substance reasonably acceptable to Seller. Seller shall cooperate with Buyer in connection with any such
notification.
ARTICLE
3
CONSIDERATION
3.1 Cash
Consideration. At the Closing, Buyer shall pay to Seller, by wire transfer of immediately available funds to the account designated
by Seller in writing prior to the Closing, the sum of One Hundred Thousand Dollars ($100,000) (the “Cash Consideration”).
3.2 Royalty.
Following the Closing, Buyer shall pay to Seller a royalty equal to ten percent (10%) of Net Revenue on all cumulative Net Revenue exceeding
Twenty Million Dollars ($20,000,000) (the “Royalty Threshold”). The aggregate royalty payments under this Section 3.2 shall
not exceed the Royalty Cap. Once cumulative royalty payments to Seller equal the Royalty Cap, no further royalty shall be owed. Royalties
shall be calculated and paid quarterly, within thirty (30) days following the end of each calendar quarter in which Net Revenue exceeds
the Royalty Threshold on a cumulative basis. Each quarterly payment shall be accompanied by a written report setting forth in reasonable
detail the calculation of Net Revenue and the royalty payment due.
3.3
Equity Interest. At the Closing, or as soon as practicable thereafter but in no event later than 60 days following the Closing,
Buyer shall, or shall cause another entity organized by Buyer to, acquire and commercialize the assets of Marizyme (such
acquisition, the “Acquisition” and such acquiring entity, the “CABG SPV”). Within 30 days after the
Acquisition, Buyer shall issue or cause to be issued to Seller a membership interest equal to four and ninety-nine hundredths
percent (4.99%) of the outstanding membership interests in the CABG SPV (the “Equity Interest”), provided that nothing
herein shall obligate Buyer or CABG SPV to act (or refrain from acting) other than in a good faith and commercially reasonable
manner. The Equity Interest shall be evidenced by an executed joinder to the CABG SPV’s operating agreement and a
corresponding membership interest certificate or written confirmation of membership. The terms of the Equity Interest shall be no
less favorable than those applicable to any other member of the CABG SPV holding a comparable membership interest. For the avoidance
of doubt, the 4.99% interest is calculated on a fully diluted basis as of the date of issuance. If Buyer fails to deliver evidence
of the Equity Interest to Seller within thirty (30) days of the Closing (subject to a five (5) business day cure period after
written notice from Seller specifying the breach), Seller shall be entitled to specific performance of this Section 3.3 in any court
of competent jurisdiction without the requirement of posting any bond or other security, the parties acknowledging that the Equity
Interest is unique in nature and that monetary damages alone would be an inadequate remedy. If, within one hundred eighty (180) days
following the Closing Date, the assets of Marizyme (or substantially all of them) are acquired by Buyer or any affiliate of Buyer
through any structure other than the CABG SPV, the Equity Interest shall be issued by the entity holding such assets on the terms
set forth herein, and references in this Agreement to the CABG SPV shall be deemed to refer to such entity.
3
3.4 Preemptive
Right. If the CABG SPV proposes to issue any new membership interests or other equity securities (each a “New Issuance”),
Buyer shall provide Seller with written notice of the proposed New Issuance at least 15 business days prior to the closing of such New
Issuance, setting forth in reasonable detail the number and type of interests to be issued, the price, and the other material terms.
Seller shall have the right, exercisable by written notice to Buyer within 10 business days of receipt of such notice, to purchase up
to its pro rata share of the New Issuance (based on Seller’s then-current percentage of outstanding membership interests in the
CABG SPV) on the same terms and conditions as those offered to other investors, for the purpose of maintaining its percentage interest
in the CABG SPV on a fully diluted basis. If Seller does not exercise this right within such 10 business day period, Seller shall be
deemed to have waived its pre-emptive right with respect to that New Issuance only. This right shall apply to each subsequent New Issuance
on the same terms.
3.5
Transfer of Equity Interest. Seller may freely sell, assign, transfer, or otherwise dispose of the Equity Interest or any portion
thereof to any third party without the consent of Buyer, subject only to applicable federal and state securities laws, and provided that
any such third party shall be reasonably acceptable to Buyer. Prior to any transfer of all or any portion of the Equity Interest to a
third party, Seller shall provide Buyer with written notice of the proposed transfer, including the proposed transferee and transfer
terms. Buyer shall have 10 business days to elect to purchase the offered interest at the same price and on the same terms. If Buyer
does not exercise this right, Seller may proceed with the transfer to the identified transferee on terms no more favorable than those
offered to Buyer. Buyer shall cooperate with Seller in connection with any such transfer, including by executing and delivering such
instruments of transfer, consents, and other documents as may be reasonably requested by Seller or a transferee to effect such transfer,
and by promptly updating the CABG SPV’s records to reflect the transfer. Any transferee of the Equity Interest shall succeed to
Seller’s rights with respect to the transferred interest, including the pre-emptive right under Section 3.6 and the registration
rights under Section 3.8. Notwithstanding the foregoing, no right of first refusal under this Section 3.7 shall apply to (a) any transfer
of the Equity Interest by Seller to an affiliate of Seller, or (b) any pledge or grant of a security interest in the Equity Interest
by Seller to a bona fide lender; provided, however, that any such transfer, pledge or grant shall be null and void without the
prior written consent of Buyer, not to be unreasonably withheld.
3.6
Registration Rights. If the CABG SPV or any successor entity converts to a corporation or otherwise becomes subject to the
Securities Act of 1933 (as amended) in connection with a public offering or otherwise, Buyer shall use commercially reasonable
efforts to cause Seller to be granted piggyback registration rights with respect to the Equity Interest, entitling Seller to include
the Equity Interest (or any securities into which it is converted) in any registration statement filed by the CABG SPV or its
successor with the Securities and Exchange Commission, subject to customary underwriter cutback provisions and market standoff
restrictions of no more than one hundred eighty (180) days. Buyer shall notify Seller in writing no later than thirty (30) days
prior to filing any such registration statement to allow Seller to exercise its piggyback rights. In addition, if the CABG SPV or
any successor entity undertakes a sale, merger, or other change of control transaction, Buyer shall use commercially reasonable
efforts to cause Seller to receive the same per-unit consideration in respect of the Equity Interest as other holders of equivalent
membership interests or shares.
3.7 No
Other Consideration. The Cash Consideration, the Royalty, and the Equity Interest constitute the entire consideration payable by
Buyer to Seller in connection with the transactions contemplated by this Agreement. No other payment is owed by either party to the other,
except as expressly set forth herein.
4
ARTICLE
4
REPRESENTATIONS AND WARRANTIES
4A.
Seller’s Representations and Warranties
Seller
represents and warrants to Buyer as of the date hereof and as of the Closing Date as follows:
4.1 Organization.
Seller is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware.
4.2 Authority.
Seller has full corporate power and authority to execute, deliver, and perform this Agreement and to consummate the transactions contemplated
hereby. The execution, delivery, and performance of this Agreement have been duly authorized by all necessary corporate action of Seller.
4.3 Ownership;
No Prior Transfer. Seller is the sole legal and beneficial holder of the Note Package. Seller has not previously sold, assigned,
pledged, hypothecated, or otherwise transferred or encumbered any interest in the Note Package to any third party.
4.4 Chain
of Title. AIxCrypto Holdings, Inc. is the successor by name change to Qualigen Therapeutics, Inc., the original lender under the
Note and secured party under the Security Agreement, as evidenced by the Certificate of Amendment attached hereto as Exhibit C. No other
transfer or assignment of the Note Package has occurred.
4.5 No
Conflicts. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby do not conflict
with or violate any material agreement to which Seller is a party or any applicable law or regulation.
4.6 No
Representation as to Collectability or Perfection. Seller makes no representation or warranty as to the collectability, enforceability,
or validity of the Note Obligations, the perfection or priority of any security interest under the Security Agreement, or the financial
condition or solvency of Marizyme. Buyer has conducted its own independent review of the Note Package and accepts the same on a quitclaim
basis as provided in Section 2.2.
4.7 Balance.
The outstanding principal balance of the Note as reflected in Seller’s books and records is $4,771,142, with interest accruing
at 18% per annum from October 2, 2025. Seller makes no representation as to the precise amount of accrued and unpaid interest as of any
date.
4.8
Co-Development Note. The Funding Amount under the Co-Development Note is $1,750,000. Seller makes no representation as to the
amount of any Investment Return, which is contingent on the commercial success of the DuraGraft product and is calculable only in
accordance with the terms of the Co-Development Note.
5
4.9 No
Prior Modifications. To Seller’s knowledge, neither Seller nor its predecessor Qualigen Therapeutics, Inc. has waived, released,
discharged, or compromised any right or obligation under the Note, the Security Agreement, or the Co-Development Note, other than as
expressly set forth in the amendments described in this Agreement. To Seller’s knowledge, no default under the Note or the Security
Agreement has been waived.
4.10 No
Litigation. Except for pending or threatened litigation, arbitration, or regulatory proceedings to which Marizyme is named as a party
or is threatened to be named as a party, there is no pending or, to Seller’s knowledge, threatened litigation, arbitration, or
regulatory proceeding relating to Seller’s interests in the Note Package, Marizyme, or the Collateral.
4.11 Liens. Seller has not granted any security interest in the Note Package to any third party.
4B.
Buyer’s Representations and Warranties
Buyer
represents and warrants to Seller as of the date hereof and as of the Closing Date as follows:
4B.1
Organization. Buyer is a limited liability company duly organized, validly existing, and in good standing under the laws of the State
of New York.
4.B.2
Authority. Buyer has full power and authority to execute, deliver, and perform this Agreement. The execution, delivery, and performance
of this Agreement have been duly authorized by all necessary action of Buyer.
4B.3
Independent Investigation. Buyer has had the opportunity to conduct such investigation as it deemed appropriate with respect to the
Note Package and the Collateral and is not relying on any representation or warranty of Seller other than those expressly set forth in
this Agreement.
4B.4
CABG SPV Formation. Buyer represents that the CABG SPV has been or will be duly formed as a New York limited liability company prior
to or at the Closing, and that Buyer has full authority to cause the CABG SPV to issue the Equity Interest to Seller as provided in Section
3.3.
ARTICLE
5
CLOSING
5.1 Closing
Date. The Closing shall occur on such date as the parties may mutually agree in writing (the “Closing Date”), and shall
be effective as of the Closing Date.
5.2 Seller’s
Closing Deliverables. At the Closing, Seller shall deliver or cause to be delivered to Buyer: (a) this Agreement, duly executed by
Seller; (b) the Allonge to the Note, in the form attached hereto as Exhibit A, duly executed by Seller; (c) the Assignment of Security
Agreement, in the form attached hereto as Exhibit B, duly executed by Seller; (d) a copy of the Certificate of Amendment attached as
Exhibit C; (e) wire instructions for the Cash Consideration; and (f) an officer’s certificate certifying the representations and
warranties made by Seller in Article 4 to be true and correct in all respects as of the Closing Date.
6
5.3
Buyer’s Closing Deliverables. At the Closing, Buyer shall deliver or cause to be delivered to Seller: (a) this Agreement,
duly executed by Buyer; (b) the Allonge to the Note, in the form attached hereto as Exhibit A, duly executed by Buyer as acceptance;
(c) the Assignment of Security Agreement, in the form attached hereto as Exhibit B, duly executed by Buyer; (d) the Cash
Consideration by wire transfer; (e) [reserved]; (f) an authorization certificate or member/manager resolution of the CABG SPV (or
Buyer, if the CABG SPV has not yet been formed) confirming the signatory’s authority to execute and deliver this Agreement and
all related documents; (g) an officer’s certificate certifying the representations and warranties made by Buyer in Article 4
to be true and correct in all respects as of the Closing Date; and (h) within thirty (30) days of the Closing, evidence of the
issuance of the Equity Interest to Seller.
5.4 Board
Consent. As a condition to Seller’s obligation to close, Seller shall have received a written consent or resolution of its
Board of Directors approving the final form of this Agreement and the transactions contemplated hereby.
5.5 Outside
Date. If the Closing has not occurred on or before [90 days from execution] (the “Outside Date”), either party may terminate
this Agreement upon written notice to the other without further liability, provided the terminating party is not then in material breach
of its obligations.
ARTICLE
6
ADDITIONAL COVENANTS
6.1 Further
Assurances. Each party agrees to execute and deliver such additional documents, instruments, and agreements, and to take such further
actions, as may be reasonably necessary or appropriate to carry out the purposes and intent of this Agreement, including the execution
and filing of UCC-3 assignment statements with the appropriate filing offices to reflect the assignment of the Security Agreement and
any related financing statements from Seller to Buyer.
6.2 Royalty
Records and Audit Rights. Buyer shall maintain accurate books and records sufficient to enable Seller to verify the calculation of
Net Revenue and royalty payments for a period of not less than three (3) years following the end of each calendar year in which royalties
may be owed. Seller shall have the right, upon thirty (30) days’ prior written notice and not more than once per calendar year,
to audit or cause an independent accountant to audit such books and records at Seller’s expense, provided that if such audit reveals
an underpayment of five percent (5%) or more, Buyer shall bear the cost of the audit.
6.3 Confidentiality.
Each party shall keep the terms and conditions of this Agreement confidential and shall not disclose the same to any third party without
the prior written consent of the other party, except (a) to such party’s legal counsel, accountants, and financial advisors on
a need-to-know basis, (b) as required by applicable law or regulation (including SEC disclosure obligations), or (c) in connection with
the enforcement of this Agreement.
6.4
CABG SPV Operating Agreement. Buyer shall provide Seller with a copy of the executed operating agreement of the CABG SPV promptly
upon its execution, and in any event within five (5) business days of execution.
7
ARTICLE
7
GENERAL PROVISIONS
7.1 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to its
conflict of laws principles.
7.2 Dispute
Resolution. Any dispute arising out of or relating to this Agreement shall be resolved by binding arbitration administered by JAMS
in New York, New York, before a single arbitrator, pursuant to the JAMS Comprehensive Arbitration Rules then in effect. The award of
the arbitrator shall be final and binding and may be entered as a judgment in any court of competent jurisdiction. Notwithstanding the
foregoing, either party may seek injunctive, provisional, or other equitable relief from any court of competent jurisdiction without
waiving its right to arbitration, and the filing of any such court proceeding shall not be deemed a waiver of the obligation to arbitrate.
7.3 Entire
Agreement. This Agreement, together with the Exhibits hereto, constitutes the entire agreement of the parties with respect to the
subject matter hereof and supersedes all prior and contemporaneous negotiations, representations, warranties, and agreements, whether
written or oral, relating to the subject matter hereof.
7.4 Amendments.
This Agreement may not be amended, modified, or supplemented except by a written instrument signed by both parties.
7.5 Waiver.
No waiver of any provision of this Agreement shall be effective unless in writing. No waiver shall be deemed a continuing waiver
or a waiver of any other provision.
7.6 Severability.
If any provision of this Agreement is held to be invalid, illegal, or unenforceable, the remaining provisions shall continue in full
force and effect.
7.7 Counterparts;
Electronic Signatures. This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument. Electronic signatures shall be deemed original signatures for all purposes.
7.8 Notices.
All notices under this Agreement shall be in writing and shall be delivered by email with confirmation of receipt, overnight courier,
or certified mail, return receipt requested, to the addresses set forth on the signature page hereof.
7.9 Assignment.
Seller may freely assign this Agreement or any rights hereunder, including the Royalty and the Equity Interest to any third party
without the consent of Buyer, subject only to applicable securities laws. Any such assignment shall be binding on Buyer upon written
notice. Buyer may freely assign this Agreement to CABG SPV or any affiliate of Buyer, but may otherwise not assign this Agreement or
any obligations hereunder without the prior written consent of Seller, which consent shall not be unreasonably withheld.
7.10 No
Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their permitted successors and assigns,
and nothing herein shall create or be deemed to create any third-party beneficiary rights.
7.11
Material Breach; Specific Performance. A material breach by Buyer of its obligations under Section 3.2 (Royalty), Section 3.3
(Equity Interest), or Section 6.2 (Royalty Records and Audit Rights), if not cured within fifteen (15) days after written notice
from Seller describing the breach in reasonable detail, shall entitle Seller to seek specific performance of such obligations in any
court of competent jurisdiction, in addition to any other remedies available at law or in equity. Buyer acknowledges that
Seller’s rights under Sections 3.2, 3.3, and 6.2 are unique and that monetary damages alone may not constitute an adequate
remedy for a breach thereof.
[
remainder of page intentionally left blank ]
8
SIGNATURE
PAGE TO NOTE PURCHASE AGREEMENT
IN
WITNESS WHEREOF, the parties have executed this Note Purchase Agreement as of the date first written above.
SELLER:
AIxCRYPTO
HOLDINGS, INC.
a
Delaware corporation
By:
/s/
Kevin A. Richardson II
Name:
Kevin
A. Richardson II
Title:
Co-Chief
Executive Officer
Date:
5/11/2026
BUYER:
CABG
ACQUISITION CORP.
a
New York limited liability company
By:
/s/Joseph
Mattia
Name:
Joseph
Mattia
Title:
Authorized
Representative
Date:
5/12/2026
Signature Page to Note
Purchase Agreement
EXHIBIT
A
Exhibit A to Note Purchase
Agreement
ALLONGE
TO AMENDED AND RESTATED
SECURED DEMAND PROMISSORY NOTE
This
Allonge (this “Allonge”) is attached to and made a part of that certain Amended and Restated Secured Demand Promissory Note
dated August 21, 2025, as amended by Amendment No. 1 dated September 15, 2025 and Amendment No. 2 dated October 2, 2025 (collectively,
the “Note”), made by Marizyme, Inc., a Nevada corporation (“Marizyme”), in favor of Qualigen Therapeutics, Inc.
(now known as AIxCrypto Holdings, Inc.), a Delaware corporation (“Endorser”).
PAY
TO THE ORDER OF CABG ACQUISITION CORP., a New York limited liability company, without recourse, representation, or warranty of any
kind, including without limitation any warranty of collectability, enforceability, perfection of security interest, or financial condition
of Marizyme.
The
limitations set forth in this Allonge are subject to and shall not limit the representations, warranties, and covenants expressly set
forth in the Note Purchase Agreement dated May 11, 2026, between Endorser and CABG Acquisition Corp.
Dated:
May 11, 2026
ENDORSER:
AIxCRYPTO
HOLDINGS, INC.
formerly
known as Qualigen Therapeutics, Inc.
By:
/s/ Kevin
A. Richardson II
Name:
Kevin
A. Richardson II
Title:
Co-Chief
Executive Officer
EXHIBIT
B
Exhibit B to Note Purchase
Agreement
ASSIGNMENT
OF SECURITY AGREEMENT
This
Assignment of Security Agreement (this “Assignment”) is entered into as of May 11, 2026, by and between AIxCrypto Holdings,
Inc. (formerly known as Qualigen Therapeutics, Inc.), a Delaware corporation (“Assignor”), and CABG Acquisition Corp., a
New York limited liability company (“Assignee”).
Recitals
Assignor
is the secured party under that certain Security Agreement dated August 20, 2025 (the “Security Agreement”), by and between
Marizyme, Inc., a Nevada corporation (“Debtor”), as debtor, and Assignor (as successor by name change to Qualigen Therapeutics,
Inc.), as secured party, granting Assignor a security interest in substantially all assets of Debtor (the “Collateral”).
Assignor desires to assign all of its right, title, and interest in and to the Security Agreement and the security interest thereunder
to Assignee, and Assignee desires to accept such assignment.
Assignment
1. Assignment.
Assignor hereby assigns, transfers, and conveys to Assignee all of Assignor’s right, title, and interest in and to: (a) the
Security Agreement; (b) the security interest in the Collateral granted thereunder; (c) any and all UCC financing statements filed in
connection with the Security Agreement; and (d) all rights and remedies of a secured party under the Security Agreement and applicable
law.
2. Quitclaim
Basis. This Assignment is made on a quitclaim basis. Assignor makes no representation or warranty as to the perfection, priority,
validity, or enforceability of the security interest assigned hereby, or as to the financial condition of Debtor. Assignee accepts this
Assignment in its as-is, where-is condition.
3. Assumption.
Assignee hereby accepts this Assignment and assumes all obligations of the secured party under the Security Agreement arising after
the effective date of this Assignment.
4. Further
Assurances. Each party agrees to execute such further documents and instruments, including UCC-3 assignment statements, as may be
reasonably necessary to give effect to this Assignment.
5. Governing
Agreement. Notwithstanding anything to the contrary herein, nothing in this Assignment shall in any way limit or modify the Note
Purchase Agreement dated May 11, 2026, between Assignor and Assignee (the “Agreement”). In the event of any conflict or inconsistency
between the terms of the Agreement and the terms hereof, the terms of the Agreement shall govern and control.
6. Governing Law. This Assignment shall be governed by the laws of the State of New York.
[
Signature page follows ]
ASSIGNOR:
AIxCRYPTO
HOLDINGS, INC.
formerly
known as Qualigen Therapeutics, Inc.
By:
/s/ Kevin A. Richardson II
Name:
Kevin
A. Richardson II
Title:
Co-Chief
Executive Officer
ASSIGNEE:
CABG
ACQUISITION CORP.
By:
/s/ Joseph Mattia
Name:
Joseph
Mattia
Title:
Authorized
Representative
Signature
Page to Assignment of Security Interest
EXHIBIT
C
CERTIFICATE
OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF QUALIGEN THERAPEUTICS, INC. (NOW KNOWN AS AIXCRYPTO HOLDINGS, INC.)
Exhibit
C to Note Purchase Agreement
State
of Delaware
Secretary
of State
Division
of Corporations
Delivered
06:24 PM 11/14/2025
FILED
06:24 PM 11/14/2025
SR
20254573811 - File Number 4601026
CERTIFICATE
OF AMENDMENT TO
THE
CERTIFICATE
OF INCORPORATION
OF
QUALJGEN
THERAPEUTICS, INC.
(Pursuant
to Section 242 of the Delaware General Corporation Law)
Qualigen
Therapeutics, Inc. (the “Corporation”), a corporation organized and
existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”),
does hereby certify that:
1.
Pursuant to Section 242 of the DGCL, this Certificate of Amendment
to the Certificate of Incorporation (this “Cettificate of Amendment”)
amends the provisions of the Certificate of Incorporation of the Corporation, as amended (the “Charter”).
2.
Upon this Certificate of Amendment becoming effective, the
Charter is hereby amended as follows: ARTICLE I of the Charter, as amended, is hereby amended and restated in its entirety to read as
follows:
FIRST:
The name of the corporation is AlxCrypto Holdings, Inc.
3.
This Certificate of Amendment has been approved and duly adopted
by the Corporation’s Board of Directors and the stockholders in accordance with the provisions of Section 242 of the DGCL.
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer as of this 14th
day of November 2025
QUALIGEN
THERAPETUICS
By:
/s/
Kevin A. Richardson II
11/14/2026
Name:
Kevin
A. Richardson II
Title:
Co-Chief
Executive Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 19
v3.26.1
Cover
May 12, 2026
Entity Addresses [Line Items]
Document Type
8-K
Amendment Flag
false
Document Period End Date
May 12, 2026
Entity File Number
001-37428
Entity Registrant Name
AIxCrypto
Holdings, Inc.
Entity Central Index Key
0001460702
Entity Tax Identification Number
26-3474527
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1990
E. Grand Ave.
Entity Address, City or Town
El
Segundo
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
90245
City Area Code
(760)
Local Phone Number
452-8111
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $0.001
Trading Symbol
AIXC
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One
5857
Owens Avenue
Entity Address, Address Line Two
Suite 300
Entity Address, City or Town
Carlsbad
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92008
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressesLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: